Om mig
- Projetledare för COMMUNITY-studien
- Medarbetare i KFC-support, ett lokalt forskarstöd i samarbete mellan Karolinska Institutet och Danderyds Sjukhus
- Koordinator för avtal som avser klinisk forskning Karolinska Institutet Danderyds Sjukhus
- Andministrator för studier registrerade i https://www.clinicaltrials.gov/ där Danderyds Sjukhus är forskningshuvudman
Publikationer:
7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Marking U, Bladh O, Havervall S, Svensson J, Greilert-Norin N, Aguilera K, Kihlgren M, Salomonsson AC, Månsson M, Gallini R, Kriegholm C, Bacchus P, Hober S, Gordon M, Blom K, Smed-Sörensen A, Åberg M, Klingström J, Thålin C Lancet Infect Dis 2023 Jan;():
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection, Sebastian Havervall, Ulrika Marking, Julia Svensson, Nina Greilert Norin, Philip Bacchus, Peter Nilsson, Sophia Hober, Max Gordon, Kim Blom, Jonas Klingström, Mikael Åberg, Anna Smed-Sörensen, Charlotte Thålin. The New England Journal of Medicine (NEJM), Letter to the Editor, online 14 september 2022, doi: 10.1056/NEJMc2209651
Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022. Blom K, Havervall S, Marking U, Norin NG, Bacchus P, Groenheit R, Bråve A, Thålin C, Klingström J Emerg Infect Dis 2022 Aug;28(10):
Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection. Blom K, Marking U, Havervall S, Norin NG, Gordon M, García M, Tecleab T, Christ W, Forsell M, Phillipson M, Nilsson P, Mangsbo S, Hober S, Åberg M, Klingström J, Thålin C Lancet Infect Dis 2022 07;22(7):943-945
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines. Marking U, Havervall S, Greilert-Norin N, Ng H, Blom K, Nilsson P, Phillipson M, Hober S, Nilsson C, Mangsbo S, Christ W, Klingström J, Gordon M, Åberg M, Thålin C Vaccines (Basel) 2022 Feb;10(3):
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time. Havervall S, Marking U, Greilert-Norin N, Gordon M, Ng H, Christ W, Phillipson M, Nilsson P, Hober S, Blom K, Klingström J, Mangsbo S, Åberg M, Thålin C Clin Transl Immunology 2022 ;11(4):e1388
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2. Havervall S, Marking U, Greilert-Norin N, Ng H, Gordon M, Salomonsson AC, Hellström C, Pin E, Blom K, Mangsbo S, Phillipson M, Klingström J, Hober S, Nilsson P, Åberg M, Thålin C EBioMedicine 2021 Aug;70():103523
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19. Havervall S, Ng H, Jernbom Falk A, Greilert-Norin N, Månberg A, Marking U, Laurén I, Gabrielsson L, Salomonsson AC, Aguilera K, Kihlgren M, Månsson M, Rosell A, Hellström C, Andersson E, Olofsson J, Skoglund L, Yousef J, Pin E, Lord M, Åberg M, Hedhammar M, Tegel H, Dönnes P, Phillipson M, Nilsson P, Klingström J, Mangsbo S, Hober S, Thålin C J Intern Med 2022 01;291(1):72-80
SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. Havervall S, Jernbom Falk A, Klingström J, Ng H, Greilert-Norin N, Gabrielsson L, Salomonsson AC, Isaksson E, Rudberg AS, Hellström C, Andersson E, Olofsson J, Skoglund L, Yousef J, Pin E, Christ W, Olausson M, Hedhammar M, Tegel H, Mangsbo S, Phillipson M, Månberg A, Hober S, Nilsson P, Thålin C PLoS One 2022 ;17(1):e0262169
Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology. Laurén I, Havervall S, Ng H, Lord M, Pettke A, Greilert-Norin N, Gabrielsson L, Chourlia A, Amoêdo-Leite C, Josyula VS, Eltahir M, Kerzeli I, Falk AJ, Hober J, Christ W, Wiberg A, Hedhammar M, Tegel H, Burman J, Xu F, Pin E, Månberg A, Klingström J, Christoffersson G, Hober S, Nilsson P, Philipson M, Dönnes P, Lindsay R, Thålin C, Mangsbo S Immun Inflamm Dis 2022 04;10(4):e595
Lundström E, Isaksson E, Greilert Norin N, Näsman P, Wester P, Mårtensson B, Norrving B, Wallén H, Borg J, Hankey Gj, Hackett Ml, Mead Ge, Dennis Ms, Sunnerhagen Ks
Stroke 2021;52(10):3082-3087